Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Good news for tirzepatide users: a 3-year look at the SURMOUNT-1 trial shows that most patients with obesity or overweight and prediabetes regained very little weight after hitting their lowest point — and nearly all held onto their blood sugar improvements. Even those who did regain more weight stayed metabolically healthier than when they started. A little rebound, it turns out, isn't necessarily a red flag.
Most people on tirzepatide for obesity or overweight with prediabetes don't regain much weight after hitting their lowest point — and even those who do still come out ahead metabolically. That's the headline from a 3-year post hoc analysis of the SURMOUNT-1 trial, published in Obesity Pillars, which tracked 690 participants across three once-weekly tirzepatide doses (5 mg, 10 mg, and 15 mg) over 176 weeks of treatment.
The findings challenge the assumption that any weight regain signals treatment failure. Across all doses, participants regained only about 3.5–4.1% of their baseline body weight from their nadir — and over 90% converted from prediabetes to normoglycemia by week 176, regardless of how much weight they regained.
By the Numbers:
Why it matters: For clinicians managing patients on long-term obesity therapy, these results offer reassurance: modest weight regain on tirzepatide doesn't erase the metabolic benefits. The drug appears to have an active pharmacological effect on cardiometabolic health beyond just the pounds lost.
